Topic Listing for Venaxis, Inc.

Administration Plan Adopted Pursuant 906 Sarbanes-oxley Act 2002
Advances Competing Technologies Development New While Securing Fda Agreements Management
Agreements Management Entered After End Alvarado Score
Amendment Executive Employment Agreement Amendments Articles Incorporation Bylaws Change
Animal Health Portfolio Animal Health Reproductive Science
Animal Healthcare Annual Report Shareholders
Appendicitis Market Appendicitis Most Common Reason Abdominal Surgery
Appendicitis Test Platform Appointment New Officers
Approved Form Content Substance Appyscore
Appyscore Blood-based Screening Triage Test Human Appendicitis Officially Appyscore Human Appendicitis Triage Blood Test
Appyscore Instrument Cassette 510 Filed Late 2010 Commercialization Appyscore Solution
Appyscreen Aspenbio Announces Management Team Changes
Aspenbio Appoints Robert Caspari Chief Operating Officer Medical Aspenbio Expands Board Addition John Landon
Aspenbio Expands Leadership Addition Daryl Faulkner Executive Chairman Aspenbio Inc Announces Closing 3072642 Private Placement
Aspenbio Inc Exact Name Registrant Specified Charter Aspenbio Patent Issuance
Aspenbio Pharma Aspenbio Pharma 510 Filing Appyscore Advances Fda Review
Aspenbio Pharma Announces End Results Sales Increase Aspenbio Pharma Announces Private Placement Common Stock
Aspenbio Pharma Announces Recent Developments Regarding Human Appendicitis Aspenbio Pharma Announces Results
Aspenbio Pharma Announces Results Corporate Updates Aspenbio Pharma Announces Successful Resolution Hurst Litigation
Aspenbio Pharma Appoints Ratain Board Directors Aspenbio Pharma Closes 182 Private Placement Common Stock
Aspenbio Pharma Completes Warrant Conversion Aspenbio Pharma Files 510 Notification Fda Appyscore Test
Aspenbio Pharma Files Fda Approval Staybred Aspenbio Pharma Inc
Aspenbio Pharma Inc Announces Closing 1428000 Private Placement Aspenbio Pharma Inc Announces Completion Private Placement Additions
Aspenbio Pharma Inc Exact Name Registrant Specified Charter Aspenbio Pharma Inc Investor Update Call Transcript 2009
Aspenbio Pharma Inc Statements Operations Aspenbio Pharma Inc Statements Operations 2009 2008
Aspenbio Pharma Inc Statements Stockholders Equity 2008 2007 Aspenbio Pharma Initiates Stock Buyback Plan
Aspenbio Pharma Investors Pay 2078000 Cash Exercise Warrants Aspenbio Pharma Proceed Fda 510 Application Appyscore
Aspenbio Pharma Reports 2006 Results Aspenbio Pharma Reports 2007 Results
Aspenbio Pharma Reports Fda 510 Clinical Trial Progress Aspenbio Pharma Reports Strong Results Appendicitis Triage Blood
Aspenbio Pharma Shares Trade Nasdaq Capital Markets Exchange Aspenbio Pharmas Human Appendicitis Blood Test Shows Strong
Aspenbio Pharmas New Human Appendicitis Blood Test Continues Aspenbio Receives Patent Office Notice Allowance Appendicitis Diagnostic
Assignment Consultation Agreement Assignment Form
Beginning Lay Ldquogroundworkrdquo Success Beneficial Ownership Reporting Compliance
Benefit Plans Board Directors
Bovine Market Opportunity Bovine Reproduction Products
Bovipure Bovipure Fsh Recombinant Product Trials Demonstrate High Success
Bovipure-fsh Caspari Broadens Aspenbios Medical Product Development Expertise Following
Certain Relationships Related Transactions Director Independence Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Chairman Department Emergency Medicine Faculty Division Infectious Diseases Changes Control
Changes Disagreements Accountants Accounting Financial Disclosure Changes Internal Control Over Financial Reporting
Check Whether Registrant Not Required Reports Pursuant Exchange Code Ethics Whistle Blower Policy
Colgin Comments
Commitments Committees
Common Stock Purchase Options Communications Board Directors
Comparative Results 2008 2007 Comparative Results 2009 2008
Comparative Results Periods 2008 2007 Comparative Results Three-month Periods 2008 2007
Compensation Discussion Analysis Compensation Other Benefits Executive Officers
Competitors Greater Resources Research Development Capabilities Not Necessary Condensed Balance Sheet
Condensed Statements Operations Conference Call
Consent Independent Registered Public Accounting Firm Consulting Development License Agreements
Consulting Other Agreements Controls Procedures
Corporate Information Critical Accounting Policies
Cts Customer Concentration
Daryl Falkner Debt Agreements
Definition Delivery Documents Shareholders Sharing Address
Departure Directors Certain Officers Election Appointment Compensatory Despite Advances133
Despite Advanceshellip Development Agreement
Directors Executive Officers Corporate Governance Early Pricing Work
Eligibility Employment Agreement Jeffrey Mcgonegal
Entry Material Definitive Agreement Environmental Protection
Equine Reproduction Products Equipure
Equipure Fsh Equity Compensation Plan Information
Evaluation Disclosure Controls Procedures Event Highlights
Exclusive Agreement Initiates Development Products Recombinant Drug Platform Executed Holder Order Exercise Option
Executive Compensation Exhibits
Expects Fda 510 Clearance Before End 2008 Ongoing Experience Manufacturing Problems Limit Growth Revenue
Explanatory Fail Obtain Fda Approval Cannot Market Certain Products
Fail Obtain Regulatory Approval Foreign Jurisdictions Then Cannot Fair Value Financial Instruments
Fda Fda 510 Clinical Trial Launched Patient Enrollments Conducted
Filing Advances Appyscore Test Worlds Blood-based Aid Diagnosis Financial Results
Financial Statement Disclosures Financial Statements Exhibits
Financing Activities Form 10-k
Form 10-k Amendment Forward Looking Statements
Forward-looking Statements General
General Operations Getting Market
Global Market Estimates Gynecological Issues Makes Female Diagnosis Difficult Resulting Appendectomies
Hellipthere Need Effective Screening Tool Human Diagnostic Antigens
Human Diagnostics Identity Background Significant Employees
Income Loss Per Share Income Tax Consequences Plan
Indemnification Certain Persons Independence Board Directors
Independent Public Accountants Index Annual Report Form 10-k
Indiscriminant Information Contact
Intellectual Property Interim Financial Statements
Inventories Investing Activities
Investment Interest Rates Investments
Issuer Purchases Equity Securities Jeffrey Mcgonegal Employment Agreement
Jim Gentric Jim Reappelle
Key Highlights Laboratory Findings
Ldquoif They Accepted Physicians Necessary Tests Cover Themrdquo Ldquoprincipal Advantages Test Better Discrimination Patients Require Surgical
Ldquothe Current Unmet Need Accuracy Diagnosis Takes Time Legal Proceedings
License Agreement License Agreements
Licensing Agreements Animal Drugs Liquidity Capital Resources
Management Management Headquarters
Managements Report Internal Control Over Financial Reporting Market Information
Market Opportunity Animal Reproduction Market Research Confirm Need Appyscore
Market Research Confirms Need Appyscore Material Modifications Rights Security Holders
Matthew Scalo Medical Reimbursement Products Development Well Changing Regulatory Environment
Meetings Board Committees Michael Merson Joins Aspenbio Pharmas Board Directors
Miscellaneous Mortgage Notes
Need Appropriate Screening Tool New Aspenbio Pharma Customer Places 600000 Order
Newly Formed Medical Advisory Board Nominees Election Directors
Not Anticipate Paying Dividends Foreseeable Future Notes Other Obligations
Notice Annual Meeting Shareholders Held 2007 Notice Annual Meeting Shareholders Held 2008
Npv Ranges 80-96 Number 001-33675
Offices Operating Activities
Other Common Stock Purchase Options Warrants Other Events
Other Information Other Installment Obligations
Other Laws Other Long Term Assets
Other Matters Other Provisions
Outstanding Equity Awards End Over 550 Patients Now Enrolled Ongoing 800 Patient
Over 700 Patients Now Enrolled Ongoing 800 Patient Overview
Page Particularly Difficult Due Common Gynecological Conditions Having Symptoms
Patients Enrolled Ongoing 800 Patient Trial Payable Related Party
Plans Commencement Fda 510 Clinical Trial Current Pre-clinical Pre-approval Policies Procedures
Pricing Learnings Pricespectives Work Principal Accountant Fees Services
Product Liability Insurance Coverage Not Sufficient Cover Claims Product Overview
Product Profile Property
Property Equipment Proposal Adoption Amendment 2002 Incentive Stock Plan
Proposal Eelection Directors Proposal Election Directors
Provision Insurance Proxy
Proxy Solicited Behalf Board Directors Proxy Statement Annual Meeting Shareholders 2007
Proxy Statement Annual Meeting Shareholders 2008 Proxy Statement Pursuant Securities Exchange Act 1934
Publication Pursuant Securities Exchange Act 1934
Quantitative Qualitative Disclosures Market Risk Quarterly Period 2008
Quarterly Period 2009 Raw Materials
Recent Sales Unregistered Securities Recently Issued Accounting Pronouncements
Recently Issued Adopted Accounting Pronouncements Reclassifications
Registrants Telephone Number Including Area Code 303 794-2000 Regulation Disclosure
Remainder Page Intentionally Left Blank Report Independent Registered Public Accounting Firm
Representations Warranties Require Additional Capital Future Cannot Assure Available Reasonable
Research Development Resignation Executive Officer Director
Results Operations Results Operations Affected Royalty Payments Due Parties
Results Operations Comparative 2009 2008 Results Operations Financial Condition
Revenue Potential Risk Factors
Robert Caspari Robert Caspari Employment Agreement
Safe Harbor Statement Science
Securities Authorized Equity Compensation Plans Information Security Ownership Certain Beneficial Owners Management
Security Ownership Certain Beneficial Owners Management Related Stockholder Settlement Agreement Release
Shareholder Communication Board Directors Shareholder Proposals
Signature Signs
Single-chain Gonadotropin Technology Breakthrough Recombinant Fsh Solicitation
Staybred Steven Wolf
Stock Stock Options
Stock Price Like Biotechnology Companies Volatile Stock Price Performance Volume Appy
Stockholders Equity Strategic Partnership
Submission Matters Vote Security Holders Subsequent Events
Success Depend Part Establishing Effective Strategic Partnerships Business Success Depends Ability Develop Commercialize New Products
Success Depends Ability Protect Intellectual Property Rights Successful Development Medical Device Such Appendicitis Test Highly
Successfully Obtain Fda Clearance Market Appendicitis Tests Experience Summary Compensation Table
Surbred Tangun
Tbd Termination Material Definitive Agreement
They Accepted Physicians Necessary Tests Cover Them Total Available Market Tam Estimates
Transactions Related Persons Trends Appendicitis Management
Trends Observations Study Unable Retain Key Employees Recruit Additional Qualified Personnel
United States Securities Exchange Washington 20549 Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Valuable
Vote Required Recommendation Board Directors Voting Rights Votes Required
What Appendicitis ~795k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki